IP Library Granted Patent US 8,993,627
Granted Patent B2
US 8,993,627 · App. 13/952,028 · Granted Mar 31, 2015

N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress

Inventor: Glenn A. Goldstein (New York, NY)
Assignee: Sentient LifeSciences, Inc.
A61K31/16C07C323/41C07C323/60C07C233/18C07C233/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,993,627
App. No.
13/952,028
Granted
Mar 31, 2015
Kind
B2
Abstract

Methods and compositions comprising N-acetylcysteine amide (NAC amide) and derivatives thereof are used in treatments and therapies for human and non-human mammalian diseases, disorders, conditions and pathologies. Pharmaceutically or physiologically acceptable compositions of NAC amide or derivatives thereof are administered alone, or in combination with other suitable agents, to reduce, prevent, or counteract oxidative stress and free radical oxidant formation and overproduction in cells and tissues, as well as to provide a new source of glutathione.

Claims (8)

1. A method of treating a human subject with a concussion comprising administering to the human subject an effective dose of N-acetylcysteine amide (NAC Amide), or a pharmaceutically acceptable salt or ester thereof, thereby treating the human subject in need of treatment concussion.

2. The method according to claim 1 , wherein the NAC Amide is administered as a prophylactic.

3. The method according to claim 1 , wherein the dose for administration is 50-10,000 mg per dose.

4. The method of claim 1 , wherein the dose for administration is 25-500 mg per dose.

5. The method of claim 1 , wherein NAC Amide is delivered orally via a capsule.

6. The method of claim 1 , wherein NAC Amide is administered subcutaneously, intravenously, intramuscularly, and intrasternally and intraperitoneally.

7. The method of claim 1 , wherein NAC Amide is administered orally, via inhalation, topically, or intranasally.

8. The method of claim 1 , wherein NAC Amide is administered before and/or after the concussion.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2014
From: GOLDSTEIN, GLENN A.
To: SENTIENT LIFESCIENCES, INC.
Reel/Frame 032586/0169 →
Continuity (5)
Continuation In Part 12707092 · Feb 17, 2010
Continuation 11912293
Provisional Application 60673561 · Apr 21, 2005
Provisional Application 60705967 · Aug 5, 2005
Related Publication 20140187640A1 · Jul 3, 2014